Gene delivery player to go public this week, aiming to raise $100M

Regenxbio's gene therapy drug delivery tech is licensed to 8 partners, including Baxalta. It is being used by 18 candidates. The Rockville, MD, company hopes to raise $100 million in its upcoming debut on the Nasdaq. In addition, Dimension Therapeutics filed with the SEC for an IPO to raise up to $115 million on the Nasdaq. It is developing gene therapies aimed at the liver for rare genetic disorders. The fate of the two companies is tied together, as Dimension licensed its adeno-associated virus (AAV) gene delivery vector from Regenexbio. More about Rengenxbio | More about Dimension

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.